What is the projected epidemiology of bronchiectasis over the next decade?
The bronchiectasis epidemiology forecast highlights the anticipated rise in diagnosed cases worldwide, particularly across the United States, Europe, Japan, and India. Currently, it is estimated that 350,000 to 500,000 adults live with bronchiectasis, a condition marked by irreversible airway widening, chronic mucus accumulation, and recurrent respiratory infections. The disease burden is not evenly distributed, with higher prevalence in females (535/100,000) compared to males (467/100,000).
As aging populations grow and chronic respiratory diseases like COPD and asthma become more prevalent, the global burden of bronchiectasis is projected to increase significantly during 2025–2034. Epidemiology reports also indicate rising healthcare costs, demand for improved treatments, and a focus on early detection to reduce exacerbations.
Bronchiectasis Disease Overview
Bronchiectasis is a chronic, progressive lung condition caused by permanent damage and dilation of the bronchi (airways). The structural changes impair mucus clearance, resulting in a cycle of infections, inflammation, and further airway injury.
Symptoms commonly include:
-
Persistent productive cough
-
Presence of thick or purulent sputum
-
Frequent chest infections
-
Wheezing and shortness of breath
-
Fatigue and reduced lung function
Causes include:
-
Severe post-infective episodes (such as pneumonia, tuberculosis, or whooping cough)
-
Chronic conditions (asthma, COPD — present in ~42% and ~36% of cases respectively)
-
Immune system deficiencies
-
Genetic conditions like cystic fibrosis
Bronchiectasis progression often results in quality of life impairments and frequent hospitalizations due to recurrent infections. This has positioned it as a public health concern in many developed and emerging markets.
Historical and Current Epidemiology (2018–2024)
During the historical period:
-
Case recognition improved due to better imaging tools like high-resolution CT scans.
-
Underdiagnosis remained a significant issue, particularly in elderly populations where symptoms overlap with COPD or asthma.
-
Post-infective bronchiectasis emerged as the most common subtype, accounting for the majority of diagnosed cases.
-
Mortality related to complications such as severe pneumonia or respiratory failure remained high among elderly patients.
By 2024 (Base Year), prevalence estimates across the 8 major markets revealed:
-
Higher rates among females compared to males.
-
Incidence trending upward in aging populations in the United States, United Kingdom, Germany, and Japan.
-
India witnessing rapid growth in diagnosed cases due to respiratory infections and increased healthcare accessibility.
Forecast Epidemiology Trends (2025–2034)
Moving into the forecast decade, epidemiological modeling suggests:
-
Stable awareness-driven growth in case detection, especially in underdiagnosed regions such as India.
-
Worsening prevalence among elderly cohorts, correlating with the rise in comorbidities like COPD.
-
Increased clustering of patients requiring chronic care due to higher hospitalization needs and exacerbations.
-
Rising economic burden on healthcare systems in Europe and North America due to treatment-dependent patients requiring prolonged care.
-
In emerging markets, higher TB and infection-related bronchiectasis cases will sustain incidence rates.
Treatment Overview and Pipeline Insights
Current Treatment Strategies
Current management is largely supportive and aims to manage symptoms, control infections, and reduce exacerbation frequency:
-
Airway clearance therapies: Chest physiotherapy, breathing exercises, and oscillation vests.
-
Antibiotics: Both oral and inhaled for controlling acute infections and preventing recurrences.
-
Bronchodilators and mucolytics: To ease airway obstruction and thin mucus.
-
Vaccinations: Against influenza and pneumococcal infections to reduce complications.
-
Pulmonary rehabilitation: Improves lung function and quality of life.
Emerging and Promising Treatments
Several novel therapies are in development, offering new hope for patients:
-
Brensocatib: A phase 3 candidate showing strong efficacy in reducing exacerbations through neutrophil serine protease inhibition.
-
BI1291583: A promising therapy targeting the airway microbiome to prevent recurrent bacterial infections.
-
Alpha 1-proteinase inhibitors: Under investigation to reduce airway inflammation and lung damage.
-
Surgical interventions: In very severe localized cases, resection may be considered.
The future treatment landscape could shift from symptomatic care toward disease-modifying therapies, improving long-term outcomes.
Epidemiology Forecast by Region (2025–2034)
-
United States: Rising prevalence linked to improved diagnostic tools and aging populations.
-
Europe (Germany, France, Italy, Spain, United Kingdom): Continued growth in prevalence due to high burden of COPD/asthma comorbidities; structured healthcare systems improving reporting.
-
Japan: Advanced healthcare access contributing to more accurate diagnosis and reported prevalence in elderly patients.
-
India: High projected growth due to post-TB bronchiectasis and infection-related cases, coupled with greater access to diagnostics.
Report Coverage: Bronchiectasis Epidemiology Forecast Report 2025–2034
The detailed epidemiology report covers:
-
Comprehensive prevalence and incidence forecasts across 8 major markets.
-
Impact of age, gender, and comorbidities in influencing disease burden.
-
Historical epidemiology data (2018–2024) and projections (2025–2034).
-
Evaluation of treatment strategies, unmet medical needs, and clinical pipeline.
-
Patterns and trends in case growth across the U.S., Europe, Asia Pacific, and emerging economies.
See More Reports
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.
Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
